Building confidence in circulating tumour DNA assays for metastatic castration-resistant prostate cancer

Genomic alterations in metastatic castration-resistant prostate cancer can be identified in plasma circulating tumour DNA. A large cohort analysis shows reliable detection of clinically relevant alterations through targeted cell-free DNA sequencing with a commercial platform, paving the way for liqu...

Full description

Saved in:
Bibliographic Details
Published in:Nature reviews. Urology 2021-05, Vol.18 (5), p.255-256
Main Authors: Ng, Sarah W. S., Wyatt, Alexander W.
Format: Article
Language:English
Subjects:
692/4028/67/1857
692/4028/67/589/466
692/4028/67/69
692/53/2423
Cancer
Circulating Tumor DNA - genetics
DNA
DNA damage
DNA sequencing
Drug therapy
Genetic aspects
Health aspects
Humans
Identification and classification
Male
Medicine
Medicine & Public Health
Metastasis
Neoplastic Cells, Circulating
News & Views
news-and-views
Nucleotide sequencing
Oncology, Experimental
Prostate cancer
Prostatic Neoplasms, Castration-Resistant - genetics
Urology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Genomic alterations in metastatic castration-resistant prostate cancer can be identified in plasma circulating tumour DNA. A large cohort analysis shows reliable detection of clinically relevant alterations through targeted cell-free DNA sequencing with a commercial platform, paving the way for liquid biopsy technology to be integrated into routine clinical practice.
ISSN:1759-4812
1759-4820
DOI:10.1038/s41585-021-00455-3